Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS)
NCT00846560 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2017-10-11
Summary
The involvement of Lymphocyte type B in Amyotrophic lateral sclerosis (ALS) patients will be compared to lymphocyte in healthy subjects.
Conditions
Sponsors & Collaborators
-
Rambam Health Care Campus
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2008-08-31
- Primary Completion
- 2009-07-31
- Completion
- 2009-07-31
Countries
- Israel
Study Locations
More Related Trials
-
Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2
NCT02059759 ·Status: COMPLETED ·Phase: PHASE2
-
IL-2 Signaling and Polarization of Regulatory LBs: Involvement in Multiple Sclerosis
NCT04697407 ·Status: COMPLETED ·Phase: NA
-
Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis
NCT03113162 ·Status: UNKNOWN ·Phase: PHASE1
-
Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis
NCT00468182 ·Status: COMPLETED
-
A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis
NCT00676156 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis
NCT04261790 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis
NCT05078177 ·Status: UNKNOWN ·Phase: PHASE1
-
A Maintenance Extension of Phase I Pilot Study of Chimeric Anti-CD4 Antibody M-T412 in Patients With Multiple Sclerosis
NCT00004816 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS
NCT02259361 ·Status: UNKNOWN ·Phase: PHASE4
-
B Cell Differentiation in MS
NCT03744351 ·Status: COMPLETED ·Phase: NA
-
Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS
NCT00638196 ·Status: TERMINATED ·Phase: PHASE1
-
Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis
NCT03493841 ·Status: COMPLETED ·Phase: PHASE1
-
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
NCT04798651 ·Status: RECRUITING ·Phase: NA
-
The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis
NCT00917839 ·Status: UNKNOWN ·Phase: PHASE2
-
Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis
NCT06495593 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
Assessing the Induction of Long-term Immune Regulation Following Treatment With Lemtrada® (Alemtuzumab).
NCT03647722 ·Status: TERMINATED
-
Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.
NCT02833714 ·Status: TERMINATED
-
T Cell Vaccination in Patients With Progressive Multiple Sclerosis
NCT01448252 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Rituximab-Induced Hypogammaglobulinemia in Multiple Sclerosis
NCT04283747 ·Status: UNKNOWN
-
Intrathecal Rituximab in Progressive Multiple Sclerosis
NCT02545959 ·Status: COMPLETED ·Phase: PHASE2
-
MUltiple Sclerosis : T Cell / B Cell Exploration
NCT04231253 ·Status: COMPLETED
-
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
NCT00879658 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients
NCT02253264 ·Status: COMPLETED ·Phase: PHASE1
-
IL-2 in Refractory Autoimmune Encephalitis
NCT02714959 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Correlation Between Cognitive Functions and MRI in Multiple Sclerosis
NCT00423111 ·Status: UNKNOWN